CA2537747A1 - The combination of a serotonin reuptake inhibitor and loxapine - Google Patents
The combination of a serotonin reuptake inhibitor and loxapine Download PDFInfo
- Publication number
- CA2537747A1 CA2537747A1 CA002537747A CA2537747A CA2537747A1 CA 2537747 A1 CA2537747 A1 CA 2537747A1 CA 002537747 A CA002537747 A CA 002537747A CA 2537747 A CA2537747 A CA 2537747A CA 2537747 A1 CA2537747 A1 CA 2537747A1
- Authority
- CA
- Canada
- Prior art keywords
- serotonin
- serotonin reuptake
- reuptake inhibitor
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention relates to the use of a combination of Loxapine and a serotonin reuptake inhibitor (SRI), for the treatment of depression and other affective disorders.
Description
The combination of a serotonin reuptake inhibitor and Loxapine The present invention relates to the use of a combination of Loxapine and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.
Background Selective serotonin reuptake inhibitors (hereinafter referred to as SSRIs) have become first choice therapeutics in the treatment of depression, certain forms of anxiety and social phobias, because they are effective, well tolerated and have a favourable safety profile compared to the classic tricyclic antidepressants.
However, clinical studies on depression and anxiety disorders indicate that non-response to SSRIs is substantial, up to 30%. Another, often neglected, factor in antidepressant treatment is compliance, which has a rather profound effect on the patient's motivation to continue pharmacotherapy.
First of all, there is the delay in therapeutic effect of SSRIs. Sometimes symptoms even 2o worsen during the first weeks of treatment. Secondly, sexual dysfunction is a side effect common to all SSRIs. Without addressing these problems, real progress in the pharmacotherapy of depression and anxiety disorders is not likely to happen.
In order to cope with non-response, psychiatrists sometimes make use of augmentation strategies. Augmentation of antidepressant therapy may be accomplished through the co-administration of mood stabilizers such as lithium carbonate or triiodothyronin or by the use of electroshock.
In 1993, an augmentation strategy with pindolol was described by Artigas et al. in Trends Pharmacol. Sci. 1993, 14, p 262-263. Artigas' idea is based on intracerebral microdialysis experiments in animals. In fact, later neurochemical studies built on the desensitization hypothesis by Blier and co-workers stated that the delay in therapeutic effect of antidepressants is related to a gradual desensitization of 5-HT autoreceptors (Blier et al. J.
Background Selective serotonin reuptake inhibitors (hereinafter referred to as SSRIs) have become first choice therapeutics in the treatment of depression, certain forms of anxiety and social phobias, because they are effective, well tolerated and have a favourable safety profile compared to the classic tricyclic antidepressants.
However, clinical studies on depression and anxiety disorders indicate that non-response to SSRIs is substantial, up to 30%. Another, often neglected, factor in antidepressant treatment is compliance, which has a rather profound effect on the patient's motivation to continue pharmacotherapy.
First of all, there is the delay in therapeutic effect of SSRIs. Sometimes symptoms even 2o worsen during the first weeks of treatment. Secondly, sexual dysfunction is a side effect common to all SSRIs. Without addressing these problems, real progress in the pharmacotherapy of depression and anxiety disorders is not likely to happen.
In order to cope with non-response, psychiatrists sometimes make use of augmentation strategies. Augmentation of antidepressant therapy may be accomplished through the co-administration of mood stabilizers such as lithium carbonate or triiodothyronin or by the use of electroshock.
In 1993, an augmentation strategy with pindolol was described by Artigas et al. in Trends Pharmacol. Sci. 1993, 14, p 262-263. Artigas' idea is based on intracerebral microdialysis experiments in animals. In fact, later neurochemical studies built on the desensitization hypothesis by Blier and co-workers stated that the delay in therapeutic effect of antidepressants is related to a gradual desensitization of 5-HT autoreceptors (Blier et al. J.
Clin. Psycipharmacol. 1987, 7 suppl. 6, 245-355). A key point in their hypothesis is that the effects of SSl2Is on the release-controlling somatodendritic autoreceptors (S-HT~A) limit the release of 5-HT in terminal areas and thus the effect of 5-HT uptake inhibition in those regions.
This is supported by microdialysis experiments in rats, showing that the increase in extracellular 5-HT elicited by a single dose of an SSRI is augmented by co-administration of a 5-HT~A autoreceptor antagonist (Invernizzi et al. Brain Res, 1992, 584, p 322-324 and Hjorth, S., J. Neurochem, 1993, 60, p 776-779).
The effect of combined administration of a compound that inhibits serotonin reuptake and a 5-HT,A receptor antagonist has been evaluated in several studies (Innis, R.B.
et al. Eur. J.
Pharmacol. 1987, 143, p. 1095-204 and Gartside, S.E., Br. J. Pharmacol, 1995, 115, p 1064-1070, Blier, P. et al. Trends in Pharmacol. Science 1994, 1 S, 220). In these studies it was found that S-HTiA receptor antagonists would abolish the initial brake on neurotransmission induced by the serotonin reuptake inhibitors and thus produce an immediate boost of 5-HT transmission and a rapid onset of therapeutic action.
Several patent applications have been filed which cover the use of a combination of a 5-HT,A antagonist and a serotonin reuptake inhibitor for the treatment of depression (see e.g.
EP-A2-687 472 and EP-A2-714 663).
Another approach to increase terminal 5-HT would be through blockade of the 5-HT~ B
autoreceptor. Microdialysis experiments in rats have indeed shown that increase of hippocampal 5-HT by citalopram is potentiated by GMC 2-29, an experimental 5-HT~B
receptor antagonist.
Several patent applications covering the combination of an SSRI and a 5-HT~ B
antagonist or partial agonist have also been filed (WO 97/28141, WO 96/03400, EP-A-701819 and WO
99/13877).
3o Summary of the invention It has now surprisingly been found that Loxapine or pharmaceutically acceptable salts thereof may be used to augment and provide faster onset of the therapeutic effect of serotonin reuptake inhibitors.
In one aspect the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
t o In another aspect the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
15 In a further aspect the invention relates to a pharmaceutical composition or kit comprising Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable Garners or diluents.
2o In a further aspect the invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound which causes an elevation in the level of extracellular serotonin, to an individual in need 25 thereof.
In a further aspect the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, for the preparation of a 3o pharmaceutical composition for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor or any other compound causing an elevation in the level of extracellular serotonin.
This is supported by microdialysis experiments in rats, showing that the increase in extracellular 5-HT elicited by a single dose of an SSRI is augmented by co-administration of a 5-HT~A autoreceptor antagonist (Invernizzi et al. Brain Res, 1992, 584, p 322-324 and Hjorth, S., J. Neurochem, 1993, 60, p 776-779).
The effect of combined administration of a compound that inhibits serotonin reuptake and a 5-HT,A receptor antagonist has been evaluated in several studies (Innis, R.B.
et al. Eur. J.
Pharmacol. 1987, 143, p. 1095-204 and Gartside, S.E., Br. J. Pharmacol, 1995, 115, p 1064-1070, Blier, P. et al. Trends in Pharmacol. Science 1994, 1 S, 220). In these studies it was found that S-HTiA receptor antagonists would abolish the initial brake on neurotransmission induced by the serotonin reuptake inhibitors and thus produce an immediate boost of 5-HT transmission and a rapid onset of therapeutic action.
Several patent applications have been filed which cover the use of a combination of a 5-HT,A antagonist and a serotonin reuptake inhibitor for the treatment of depression (see e.g.
EP-A2-687 472 and EP-A2-714 663).
Another approach to increase terminal 5-HT would be through blockade of the 5-HT~ B
autoreceptor. Microdialysis experiments in rats have indeed shown that increase of hippocampal 5-HT by citalopram is potentiated by GMC 2-29, an experimental 5-HT~B
receptor antagonist.
Several patent applications covering the combination of an SSRI and a 5-HT~ B
antagonist or partial agonist have also been filed (WO 97/28141, WO 96/03400, EP-A-701819 and WO
99/13877).
3o Summary of the invention It has now surprisingly been found that Loxapine or pharmaceutically acceptable salts thereof may be used to augment and provide faster onset of the therapeutic effect of serotonin reuptake inhibitors.
In one aspect the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
t o In another aspect the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
15 In a further aspect the invention relates to a pharmaceutical composition or kit comprising Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable Garners or diluents.
2o In a further aspect the invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound which causes an elevation in the level of extracellular serotonin, to an individual in need 25 thereof.
In a further aspect the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, for the preparation of a 3o pharmaceutical composition for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor or any other compound causing an elevation in the level of extracellular serotonin.
In a further aspect the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, for the preparation of a kit for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor or any other compound causing an elevation in the level of extracellular serotonin.
In a further aspect the invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor, or any other compound 1o which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.
15 In an embodiment the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular 2o depression.
In a further embodiment the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of anxiety disorders including general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute 25 stress disorder, post trauma stress disorder or social anxiety disorder.
In a further embodiment, the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of psychoses, including schizophrenia and schizoaffective disorders.
In a further embodiment the serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds. Just to clarify, each of the serotonin reuptake inhibitors specified above is intended to be an individual embodiment. Accordingly, each of them and the use thereof may be claimed individually.
In a further preferred embodiement, the serotonin reuptake inhibitor is escitalopram.
In a further preferred embodiment, the serotonin reuptake inhibitor is citalopram.
In a further embodiment the serotonin reuptake inhibitor is a selective serotonin reuptake l0 inhibitor (SSRI).
In a further embodiment the pharmaceutical composition or kit prepared is adapted for simultaneous administration of the active ingredients. In an embodiment the active ingredients are contained in the same unit dosage form.
In a further embodiment the pharmaceutical composition or kit prepared is adapted for sequential administration of the active ingredients. In an embodiment the active ingredients are contained in discrete unit dosage forms.
Description of the invention The present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
In particular, the present invention relates to the use of Loxapine or a pharmaceutically 3o acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonm.
More particularly, the present invention relates to the use as above, of Loxapine, or a pharmaceutically acceptable salt thereof, for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis including schizophrenia and schizoaffective disorders and drug abuse, in particular depression, in combination with a serotonin reuptake inhibitor or to any other compound, which causes an elevation in the level of extracellular serotonin.
The anxiety disorders mentioned above include general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
As used herein, the term augmenting covers improving the therapeutic effect andlor potentiating the therapeutic effect of an SRI or a compound which causes an elevation in the level of extracellular 5-HT.
In a further embodiment, the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the preparation of a pharmaceutical composition for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
In a further embodiment, the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the 3o preparation of a kit-of parts (kit) for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
The diseases responsive to a serotonin reuptake inhibitor include depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, including schizophrenia and schizoaffective disorders, psychosis, including schizophrenia and schizoaffective disorders and drug abuse, in particular depression.
The term anxiety disorders is as defined above.
1o In one embodiment, the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition as above, which is adapted for simultaneous administration of the active ingredients. In particular, such pharmaceutical compositions may contain the active ingredients within the same unit dosage form, e.g. in the same tablet or capsule. Such unit 15 dosage forms may contain the active ingredients as a homogenous mixture or in separate compartments of the unit dosage form.
In another embodiment, the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical 2o composition or kit as above, which is adapted for sequential administration of the active ingredients. In particular, such pharmaceutical compositions may contain the active ingredients in discrete unit dosage forms, e.g. discrete tablets or capsules containing either of the active ingredients. These discrete unit dosage forms may be contained in the same container or package, e.g. a blister pack.
As used herein the term kit means a pharmaceutical composition containing each of the active ingredients, but in discrete unit dosage forms.
The invention also relates to a pharmaceutical composition or kit comprising Loxapine or a 3o pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound, which causes an elevation in extracellular 5-HT, and optionally pharmaceutically acceptable carriers or diluents.
The pharmaceutical composition or kit of the invention may be adapted for simultaneous administration of the active ingredients or for sequential administration of the active ingredients, as described above.
Finally, the present invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, to an individual in need thereof.
In particular, the present invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
The individuals, which may benefit from treatment with a combination as above, may suffer from depression, anxiety disorders and other affective disorders, psychosis, eating disorders 2o such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, and drug abuse, in particular depression.
As mentioned above, anxiety disorder includes general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
Psychosis includes but is not limited to schizophrenia and schizoaffective disorders.
3o Loxapine and the serotonin reuptake inhibitor may be administered simultaneously as described above.
Alternatively, the active ingredients may be administered sequentially, e.g.
in two discrete unit dosage forms as described above.
It has now, surprisingly, been found that co-administration of Loxapine and a serotonin reuptake inhibitor produces a significant increased response in an animal model predictive of antidepressant effect, the 5-HT microdialysis model, compared to the administration of the serotonin reuptake inhibitor alone. Administration of Loxapine alone causes no significant effect in the experiments.
1 o As mentioned above, serotonin reuptake inhibitors show delayed onset of action. Even in responders to SSRIs, several weeks of treatment are necessary to achieve a relief in symptoms.
Loxapine may provide fast onset of therapeutic effect of serotonin reuptake inhibitors.
The use of a combination of Loxapine and a serotonin reuptake inhibitor may greatly reduce 15 the amount of serotonin reuptake inhibitor necessary to treat depression and other affective disorders and may thus reduce the side effects caused by the serotonin reuptake inhibitor. In particular, the combination of a reduced amount of SRI and Loxapine may reduce the risk of SSRI-induced sexual dysfunction and sleep disturbances.
20 Co-administration of Loxapine and a serotonin reuptake inhibitor may also be useful for the treatment of refractory depression, i.e. depression, which cannot be treated appropriately by administration of a serotonin reuptake inhibitor alone. Typically, Loxapine may be used as add-on therapy for the augmentation of the response to SRIs in patients where at least 40-60%
reduction in symptoms has not been achieved during the first 6 weeks of treatment with an 25 SRI.
Many antidepressants with serotonin reuptake inhibiting effect have been described in the literature. Any pharmacologically active compound which primarily or partly exerts its therapeutic effect via inhibition of serotonin reuptake in the CNS, may benefit from 30 augmentation with Loxapine.
The following list contains a number of serotonin reuptake inhibitors, which may benefit from augmentation with Loxapine: citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, 5 milnacipran, bazinaprine, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, Loxapine, nitroxazepine, McN
5652, McN 5707, Ol 77, Org 6582, Org 6997, Org 6906, amitriptyline, amitriptyline N-oxide, nortriptyline, CL 255.663, pirlindole, indatraline, LY 113.821, LY
214.281, CGP
6085 A, RU 25.591, napamezole, diclofensine, trazodone, EMD 68.843, BMY
42.569, NS
10 2389, sercloremine, nitroquipazine, ademethionine, sibutramine and clovoxamine. The compounds mentioned above may be used in the form of the base or a pharmaceutically acceptable acid addition salt thereof. Each of the serotonin reuptake inhibitors specified above is intended to be an individual embodiment. Accordingly, each of them and the use thereof may be claimed individually.
Typically, compounds such as citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, desmethylvenlafaxine, duloxetine, dapoxetine, vilazodone, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, imeldine, ifoxetine, indeloxazine, tiflucarbine, viqualine, milnacipran, bazinaprine, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, Loxapine, nitroxazepine, roxindole, amitriptyline, amitriptyline N-oxide, nortriptyline, pirlindole, indatraline, napamezole, diclofensine, trazodone, sercloremine, nitroquipazine, ademethionine, sibutramine, desmethylsubitramine, didesmethylsubitramine, clovoxamine vilazodone, N-[( 1-[(6-Fluoro-2-naphthalenyl)methyl]- 4-piperidinyl]amino]carbonyl]-3-pyridine carboxamide (WY 27587), [trans-6-(2-chlorophenyl)-1,2,3,5,6,1Ob-hexahydropyrrolo- (2,1-a)isoquinoline]
(McN
5707), (dl-4-exo-amino-8-chloro-benzo-(b)-bicyclo[3.3.1]nona-2-6 alpha(10 alpha)-dime hydrochloride)(Org 6997), (dl)-(5 alpha,8 alpha,9 alpha)-5,8,9,10-Tetrahydro-5,9- methanobenzocycloocten-8-amine hydrochloride (Org 6906), -[2-[4-(6-fluoro-1 H-indol-3-yl)-3,6-dihydro-1 (2H)-pyridinyl]ethyl]-3-isopropyl-6-(methylsulphonyl)-3,4-dihydro-1H-2,1,3-benzothiadiazine-2,2-dioxide (LY393558), [4-(5,6-dimethyl-2-benzofuranyl)-piperidine] (CGP 6085), dimethyl-[5-(4-nitro-phenoxy)-6,7,8,9-tetrahydro-SH-benzocyclohepten-7-yl]-amine (RU
25.591 ), ~I
I~
(A 80426), N . I ~ N~=
"' ~'I
(EMD 86006), (533005), N o (OPC 14523), o~~o H°~~f'~°
(McN 5652), ~N
H
CIH
(YM 3 S 992), s N-OH
(Org 6582), are suitable as SRIs. The compounds mentioned above may be used in the form of the base or a pharmaceutically acceptable acid addition salt thereof. Each of the serotonin reuptake l0 inhibitors specified above is intended to be an individual embodiment.
Accordingly, each of them and the use thereof may be claimed individually.
Other therapeutic compounds which may benefit from augmentation with Loxapine include compounds, which causes an elevation in the extracellular level of S-HT in the synaptic 15 cleft, although they are not serotonin reuptake inhibitors. One such compound is tianeptine.
The above list of serotonin reuptake inhibitors and other compounds, which causes an increase in the extracellular level of serotonin, may not be construed as limiting.
In an embodiment the SRIs is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine. Just to clarify, each of these SRIs constitute individual embodiments, and may be the subject of individual claims.
The term selective serotonin reuptake inhibitor (SSRI) means an inhibitor of the monoamine transporters which has stronger inhibitory effect at the serotonin transporter than the dopamine and the noradrenaline transporters.
Selective serotonin reuptake inhibitors (SSRIs) are among the most preferred serotonin reuptake inhibitors used according to the present invention. Thus in a further embodiment the SRI is selected from SSRIs, such as citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline or paroxetine.
The active ingredients according to the invention, i.e. Loxapine and the SRI
or a compound 2o causing an increase in extracellular serotonin levels, may be used in the free base form or in the form of a pharmaceutically acceptable acid addition salt thereof, the latter being obtainable by reaction of the base form with an appropriate acid.
Citalopram is preferably used in the form of the hydrobromide or as the base, escitalopram in the form of the oxalate, fluoxetine, sertraline and paroxetine in the form of the hydrochloride and fluvoxamine in the form of the maleate.
As mentioned above, the combination of Loxapine with a serotonin reuptake inhibitor unexpectedly shows a synergistic effect on the central nervous system (CNS).
As a 3o consequence, combination therapy using Loxapine and lower doses of the serotonin reuptake inhibitor than normally used in monotherapy, may be effective, and side-effects associated with the larger amounts of serotonin reuptake inhibitor used in monotherapy may be reduced or prevented altogether.
Additionally, combination therapy with Loxapine using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs.
The amount of Loxapine used in combination therapy may range from about 0.001 to about 1 g/day, such as from about 0.001 to about 0.1 mg/day, about 0.1 to about 1 mg/day, about 1 mg/day to about 10 mg/day, about 10 mg/day to about 100 mg/day and from about mg/day to about 1 g/day.
Serotonin reuptake inhibitors, including the SSRIs specifically mentioned hereinabove, differ both in molecular weight and in activity. As a consequence, the amount of serotonin reuptake inhibitor used in combination therapy depends on the nature of said serotonin reuptake inhibitor. In one embodiment of the invention, the serotonin reuptake inhibitor or 15 the compound causing an increase in the level of extracellular 5-HT, is administered at lower doses than required when the compound is used alone. In another embodiment, the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT, is administered in normal doses.
20 To prepare the pharmaceutical compositions of this invention, an appropriate amount of the active ingredient(s), in salt form or base form, is combined in an intimate admixture with a pharmaceutically acceptable Garner, which can take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable for administration orally, rectally, percutaneously 25 or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid Garners such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules 3o and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. As used in the specification and claims, unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredients) calculated to produce the desired therapeutic effect, in association with the required pharmaceutical Garner. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
1o Loxapine may be administered before, during or after the administration of the serotonin reuptake inhibitor provided that the time between the administration of Loxapine and the administration of the serotonin reuptake inhibitor is such that ingredients are allowed to act synergistically on the CNS. When simultaneous administration of Loxapine and a serotonin reuptake inhibitor is envisaged, a composition containing both a serotonin reuptake inhibitor 15 and Loxapine may be particularly convenient. Alternatively, Loxapine and the serotonin reuptake inhibitor may be administered separately in the form of suitable compositions. The compositions may be prepared as described hereinabove.
The present invention also comprises products containing Loxapine and a serotonin 2o reuptake inhibitor as a combination preparation for simultaneous, separate or sequential use in psychiatric drug therapy. Such products may comprise, for example, a kit comprising discrete unit dosage forms containing Loxapine and discrete unit dosage forms containing a serotonin reuptake inhibitor, all contained in the same container or pack, e.g. a blister pack.
The above mentioned preparations for simultaneous or sequential administration may instead of a serotonin reuptake inhibitor contain another compound causing an elevation in the level of extracellular 5-HT.
Experimental part Animals Male albino rats of a Wistar-derived strain (285-320 g; Harlan, Zeist, The Netherlands) were used for the experiments. Upon surgery, rats were housed individually in plastic cages (35 x 35 x 40 cm), and had free access to food and water. Animals were kept on a 12 h light schedule (light on 7:00 a.m.). The experiments are concordant with the declarations of Helsinki and were approved by the animal care committee of the faculty of mathematics and natural science of the University of Groningen.
Drugs The following drugs were used: escitalopram oxalate and loxapine (Lundbeck A/S, Copenhagen, Denmark) Surgery Microdialysis of brain serotonin levels was performed using home made I-shaped probes, made of polyacrylonitrile / sodium methyl sulfonate copolymer dialysis fiber (i.d. 220 p,m, o.d. 0.31 pm, AN 69, Hospal, Italy). Preceding surgery rats were anaesthetised using isoflurane (OZ/N20; 300/300m1/min). Lidocaine-HCI, 10 % (m/v) was used for local anaesthesia. Rats were placed in a stereotaxic frame (Kopf, USA), and probes were inserted into Ventral Hippocampus (V. Hippo, L +4.8 mm, IA: +3.7 mm, V: -8.0 mm) (Paxinos and Watson, 1982). After insertion, probes were secured with dental cement.
Microdialysis experiments Rats were allowed to recover for at least 24 h. Probes were perfused with artificial cerebrospinal fluid containing 147 mM NaCI, 3.0 mM KCI, 1.2 mM CaCl2, and 1.2 mM
MgCl2, at a flow-rate of 1.5 pl / min (Harvard apparatus, South Natick, Ma., USA). 15 minute microdialysis samples were collected in HPLC vials containing 7.5 p,l 0.02 M acetic acid for serotonin analysis.
Serotonin analysis:
Twenty-pl microdialysate samples were injected via an autoinjector (CMA/200 refrigerated microsampler, CMA, Sweden) onto a 100 x 2.0 mm C18 Hypersil 3 p,m column (Bester, Amstelveen, the Netherlands) and separated with a mobile phase consisting of 5 g/L di-ammoniumsulfate, 500 mg/L EDTA, 50 mg/L heptane sulphonic acid, 4 % methanol v/v, and 30 ~llL of triethylamine, pH 4.65 at a flow of 0.4 ml/min (Shimadzu LC-10 AD). 5-HT was detected amperometrically at a glassy carbon electrode at 500 mV vs Ag/AgCI
(Antec Leyden, Leiden, The Netherlands). The detection limit was 0.5 fmol 5-HT
per 20 ~1 sample (signal to noise ratio 3).
Data presentation and statistics Four consecutive microdialysis samples with less then 20 % variation were taken as control to and set at 100 %. Data are presented as percentages of control level (mean + S.E.M.) in time. Statistical analysis was performed using Sigmastat for Windows (SPSS, Jandel Corporation). Treatments were compared versus controls using two way analysis of variance (ANOVA) for repeated measurements, followed by Student Newman Keuls test.
Drug effects were evaluated using one way ANOVA for repeated measures on ranks. Level of significance level was set at p<0.05.
Results Co-administration of escitalopram with loxapine on 5-HT levels in ventral hippocampus Administration of loxapine did not induce any significant effects on 5-HT
levels X2~o=10.0, P=0.44). Co-administration of escitalopram (1.5 ~mol/kg s.c.) with 0.1 ~.mollkg s.c. of loxapine induced a significant augmented effect on hippocampal S-HT levels (Treatment F(1,9)= 5.95, P=0.0372, Treatment vs. Time F(1,G4)= 4.18, P=0.0014). Posthoc analysis revealed significance at t= 45 and 60 minutes after injection (see Fig. 1).
In a further aspect the invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor, or any other compound 1o which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.
15 In an embodiment the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular 2o depression.
In a further embodiment the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of anxiety disorders including general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute 25 stress disorder, post trauma stress disorder or social anxiety disorder.
In a further embodiment, the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of psychoses, including schizophrenia and schizoaffective disorders.
In a further embodiment the serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds. Just to clarify, each of the serotonin reuptake inhibitors specified above is intended to be an individual embodiment. Accordingly, each of them and the use thereof may be claimed individually.
In a further preferred embodiement, the serotonin reuptake inhibitor is escitalopram.
In a further preferred embodiment, the serotonin reuptake inhibitor is citalopram.
In a further embodiment the serotonin reuptake inhibitor is a selective serotonin reuptake l0 inhibitor (SSRI).
In a further embodiment the pharmaceutical composition or kit prepared is adapted for simultaneous administration of the active ingredients. In an embodiment the active ingredients are contained in the same unit dosage form.
In a further embodiment the pharmaceutical composition or kit prepared is adapted for sequential administration of the active ingredients. In an embodiment the active ingredients are contained in discrete unit dosage forms.
Description of the invention The present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
In particular, the present invention relates to the use of Loxapine or a pharmaceutically 3o acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonm.
More particularly, the present invention relates to the use as above, of Loxapine, or a pharmaceutically acceptable salt thereof, for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis including schizophrenia and schizoaffective disorders and drug abuse, in particular depression, in combination with a serotonin reuptake inhibitor or to any other compound, which causes an elevation in the level of extracellular serotonin.
The anxiety disorders mentioned above include general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
As used herein, the term augmenting covers improving the therapeutic effect andlor potentiating the therapeutic effect of an SRI or a compound which causes an elevation in the level of extracellular 5-HT.
In a further embodiment, the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the preparation of a pharmaceutical composition for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
In a further embodiment, the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the 3o preparation of a kit-of parts (kit) for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
The diseases responsive to a serotonin reuptake inhibitor include depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, including schizophrenia and schizoaffective disorders, psychosis, including schizophrenia and schizoaffective disorders and drug abuse, in particular depression.
The term anxiety disorders is as defined above.
1o In one embodiment, the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition as above, which is adapted for simultaneous administration of the active ingredients. In particular, such pharmaceutical compositions may contain the active ingredients within the same unit dosage form, e.g. in the same tablet or capsule. Such unit 15 dosage forms may contain the active ingredients as a homogenous mixture or in separate compartments of the unit dosage form.
In another embodiment, the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical 2o composition or kit as above, which is adapted for sequential administration of the active ingredients. In particular, such pharmaceutical compositions may contain the active ingredients in discrete unit dosage forms, e.g. discrete tablets or capsules containing either of the active ingredients. These discrete unit dosage forms may be contained in the same container or package, e.g. a blister pack.
As used herein the term kit means a pharmaceutical composition containing each of the active ingredients, but in discrete unit dosage forms.
The invention also relates to a pharmaceutical composition or kit comprising Loxapine or a 3o pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound, which causes an elevation in extracellular 5-HT, and optionally pharmaceutically acceptable carriers or diluents.
The pharmaceutical composition or kit of the invention may be adapted for simultaneous administration of the active ingredients or for sequential administration of the active ingredients, as described above.
Finally, the present invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, to an individual in need thereof.
In particular, the present invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
The individuals, which may benefit from treatment with a combination as above, may suffer from depression, anxiety disorders and other affective disorders, psychosis, eating disorders 2o such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, and drug abuse, in particular depression.
As mentioned above, anxiety disorder includes general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
Psychosis includes but is not limited to schizophrenia and schizoaffective disorders.
3o Loxapine and the serotonin reuptake inhibitor may be administered simultaneously as described above.
Alternatively, the active ingredients may be administered sequentially, e.g.
in two discrete unit dosage forms as described above.
It has now, surprisingly, been found that co-administration of Loxapine and a serotonin reuptake inhibitor produces a significant increased response in an animal model predictive of antidepressant effect, the 5-HT microdialysis model, compared to the administration of the serotonin reuptake inhibitor alone. Administration of Loxapine alone causes no significant effect in the experiments.
1 o As mentioned above, serotonin reuptake inhibitors show delayed onset of action. Even in responders to SSRIs, several weeks of treatment are necessary to achieve a relief in symptoms.
Loxapine may provide fast onset of therapeutic effect of serotonin reuptake inhibitors.
The use of a combination of Loxapine and a serotonin reuptake inhibitor may greatly reduce 15 the amount of serotonin reuptake inhibitor necessary to treat depression and other affective disorders and may thus reduce the side effects caused by the serotonin reuptake inhibitor. In particular, the combination of a reduced amount of SRI and Loxapine may reduce the risk of SSRI-induced sexual dysfunction and sleep disturbances.
20 Co-administration of Loxapine and a serotonin reuptake inhibitor may also be useful for the treatment of refractory depression, i.e. depression, which cannot be treated appropriately by administration of a serotonin reuptake inhibitor alone. Typically, Loxapine may be used as add-on therapy for the augmentation of the response to SRIs in patients where at least 40-60%
reduction in symptoms has not been achieved during the first 6 weeks of treatment with an 25 SRI.
Many antidepressants with serotonin reuptake inhibiting effect have been described in the literature. Any pharmacologically active compound which primarily or partly exerts its therapeutic effect via inhibition of serotonin reuptake in the CNS, may benefit from 30 augmentation with Loxapine.
The following list contains a number of serotonin reuptake inhibitors, which may benefit from augmentation with Loxapine: citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, 5 milnacipran, bazinaprine, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, Loxapine, nitroxazepine, McN
5652, McN 5707, Ol 77, Org 6582, Org 6997, Org 6906, amitriptyline, amitriptyline N-oxide, nortriptyline, CL 255.663, pirlindole, indatraline, LY 113.821, LY
214.281, CGP
6085 A, RU 25.591, napamezole, diclofensine, trazodone, EMD 68.843, BMY
42.569, NS
10 2389, sercloremine, nitroquipazine, ademethionine, sibutramine and clovoxamine. The compounds mentioned above may be used in the form of the base or a pharmaceutically acceptable acid addition salt thereof. Each of the serotonin reuptake inhibitors specified above is intended to be an individual embodiment. Accordingly, each of them and the use thereof may be claimed individually.
Typically, compounds such as citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, desmethylvenlafaxine, duloxetine, dapoxetine, vilazodone, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, imeldine, ifoxetine, indeloxazine, tiflucarbine, viqualine, milnacipran, bazinaprine, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, Loxapine, nitroxazepine, roxindole, amitriptyline, amitriptyline N-oxide, nortriptyline, pirlindole, indatraline, napamezole, diclofensine, trazodone, sercloremine, nitroquipazine, ademethionine, sibutramine, desmethylsubitramine, didesmethylsubitramine, clovoxamine vilazodone, N-[( 1-[(6-Fluoro-2-naphthalenyl)methyl]- 4-piperidinyl]amino]carbonyl]-3-pyridine carboxamide (WY 27587), [trans-6-(2-chlorophenyl)-1,2,3,5,6,1Ob-hexahydropyrrolo- (2,1-a)isoquinoline]
(McN
5707), (dl-4-exo-amino-8-chloro-benzo-(b)-bicyclo[3.3.1]nona-2-6 alpha(10 alpha)-dime hydrochloride)(Org 6997), (dl)-(5 alpha,8 alpha,9 alpha)-5,8,9,10-Tetrahydro-5,9- methanobenzocycloocten-8-amine hydrochloride (Org 6906), -[2-[4-(6-fluoro-1 H-indol-3-yl)-3,6-dihydro-1 (2H)-pyridinyl]ethyl]-3-isopropyl-6-(methylsulphonyl)-3,4-dihydro-1H-2,1,3-benzothiadiazine-2,2-dioxide (LY393558), [4-(5,6-dimethyl-2-benzofuranyl)-piperidine] (CGP 6085), dimethyl-[5-(4-nitro-phenoxy)-6,7,8,9-tetrahydro-SH-benzocyclohepten-7-yl]-amine (RU
25.591 ), ~I
I~
(A 80426), N . I ~ N~=
"' ~'I
(EMD 86006), (533005), N o (OPC 14523), o~~o H°~~f'~°
(McN 5652), ~N
H
CIH
(YM 3 S 992), s N-OH
(Org 6582), are suitable as SRIs. The compounds mentioned above may be used in the form of the base or a pharmaceutically acceptable acid addition salt thereof. Each of the serotonin reuptake l0 inhibitors specified above is intended to be an individual embodiment.
Accordingly, each of them and the use thereof may be claimed individually.
Other therapeutic compounds which may benefit from augmentation with Loxapine include compounds, which causes an elevation in the extracellular level of S-HT in the synaptic 15 cleft, although they are not serotonin reuptake inhibitors. One such compound is tianeptine.
The above list of serotonin reuptake inhibitors and other compounds, which causes an increase in the extracellular level of serotonin, may not be construed as limiting.
In an embodiment the SRIs is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine. Just to clarify, each of these SRIs constitute individual embodiments, and may be the subject of individual claims.
The term selective serotonin reuptake inhibitor (SSRI) means an inhibitor of the monoamine transporters which has stronger inhibitory effect at the serotonin transporter than the dopamine and the noradrenaline transporters.
Selective serotonin reuptake inhibitors (SSRIs) are among the most preferred serotonin reuptake inhibitors used according to the present invention. Thus in a further embodiment the SRI is selected from SSRIs, such as citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline or paroxetine.
The active ingredients according to the invention, i.e. Loxapine and the SRI
or a compound 2o causing an increase in extracellular serotonin levels, may be used in the free base form or in the form of a pharmaceutically acceptable acid addition salt thereof, the latter being obtainable by reaction of the base form with an appropriate acid.
Citalopram is preferably used in the form of the hydrobromide or as the base, escitalopram in the form of the oxalate, fluoxetine, sertraline and paroxetine in the form of the hydrochloride and fluvoxamine in the form of the maleate.
As mentioned above, the combination of Loxapine with a serotonin reuptake inhibitor unexpectedly shows a synergistic effect on the central nervous system (CNS).
As a 3o consequence, combination therapy using Loxapine and lower doses of the serotonin reuptake inhibitor than normally used in monotherapy, may be effective, and side-effects associated with the larger amounts of serotonin reuptake inhibitor used in monotherapy may be reduced or prevented altogether.
Additionally, combination therapy with Loxapine using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs.
The amount of Loxapine used in combination therapy may range from about 0.001 to about 1 g/day, such as from about 0.001 to about 0.1 mg/day, about 0.1 to about 1 mg/day, about 1 mg/day to about 10 mg/day, about 10 mg/day to about 100 mg/day and from about mg/day to about 1 g/day.
Serotonin reuptake inhibitors, including the SSRIs specifically mentioned hereinabove, differ both in molecular weight and in activity. As a consequence, the amount of serotonin reuptake inhibitor used in combination therapy depends on the nature of said serotonin reuptake inhibitor. In one embodiment of the invention, the serotonin reuptake inhibitor or 15 the compound causing an increase in the level of extracellular 5-HT, is administered at lower doses than required when the compound is used alone. In another embodiment, the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT, is administered in normal doses.
20 To prepare the pharmaceutical compositions of this invention, an appropriate amount of the active ingredient(s), in salt form or base form, is combined in an intimate admixture with a pharmaceutically acceptable Garner, which can take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable for administration orally, rectally, percutaneously 25 or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid Garners such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules 3o and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. As used in the specification and claims, unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredients) calculated to produce the desired therapeutic effect, in association with the required pharmaceutical Garner. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
1o Loxapine may be administered before, during or after the administration of the serotonin reuptake inhibitor provided that the time between the administration of Loxapine and the administration of the serotonin reuptake inhibitor is such that ingredients are allowed to act synergistically on the CNS. When simultaneous administration of Loxapine and a serotonin reuptake inhibitor is envisaged, a composition containing both a serotonin reuptake inhibitor 15 and Loxapine may be particularly convenient. Alternatively, Loxapine and the serotonin reuptake inhibitor may be administered separately in the form of suitable compositions. The compositions may be prepared as described hereinabove.
The present invention also comprises products containing Loxapine and a serotonin 2o reuptake inhibitor as a combination preparation for simultaneous, separate or sequential use in psychiatric drug therapy. Such products may comprise, for example, a kit comprising discrete unit dosage forms containing Loxapine and discrete unit dosage forms containing a serotonin reuptake inhibitor, all contained in the same container or pack, e.g. a blister pack.
The above mentioned preparations for simultaneous or sequential administration may instead of a serotonin reuptake inhibitor contain another compound causing an elevation in the level of extracellular 5-HT.
Experimental part Animals Male albino rats of a Wistar-derived strain (285-320 g; Harlan, Zeist, The Netherlands) were used for the experiments. Upon surgery, rats were housed individually in plastic cages (35 x 35 x 40 cm), and had free access to food and water. Animals were kept on a 12 h light schedule (light on 7:00 a.m.). The experiments are concordant with the declarations of Helsinki and were approved by the animal care committee of the faculty of mathematics and natural science of the University of Groningen.
Drugs The following drugs were used: escitalopram oxalate and loxapine (Lundbeck A/S, Copenhagen, Denmark) Surgery Microdialysis of brain serotonin levels was performed using home made I-shaped probes, made of polyacrylonitrile / sodium methyl sulfonate copolymer dialysis fiber (i.d. 220 p,m, o.d. 0.31 pm, AN 69, Hospal, Italy). Preceding surgery rats were anaesthetised using isoflurane (OZ/N20; 300/300m1/min). Lidocaine-HCI, 10 % (m/v) was used for local anaesthesia. Rats were placed in a stereotaxic frame (Kopf, USA), and probes were inserted into Ventral Hippocampus (V. Hippo, L +4.8 mm, IA: +3.7 mm, V: -8.0 mm) (Paxinos and Watson, 1982). After insertion, probes were secured with dental cement.
Microdialysis experiments Rats were allowed to recover for at least 24 h. Probes were perfused with artificial cerebrospinal fluid containing 147 mM NaCI, 3.0 mM KCI, 1.2 mM CaCl2, and 1.2 mM
MgCl2, at a flow-rate of 1.5 pl / min (Harvard apparatus, South Natick, Ma., USA). 15 minute microdialysis samples were collected in HPLC vials containing 7.5 p,l 0.02 M acetic acid for serotonin analysis.
Serotonin analysis:
Twenty-pl microdialysate samples were injected via an autoinjector (CMA/200 refrigerated microsampler, CMA, Sweden) onto a 100 x 2.0 mm C18 Hypersil 3 p,m column (Bester, Amstelveen, the Netherlands) and separated with a mobile phase consisting of 5 g/L di-ammoniumsulfate, 500 mg/L EDTA, 50 mg/L heptane sulphonic acid, 4 % methanol v/v, and 30 ~llL of triethylamine, pH 4.65 at a flow of 0.4 ml/min (Shimadzu LC-10 AD). 5-HT was detected amperometrically at a glassy carbon electrode at 500 mV vs Ag/AgCI
(Antec Leyden, Leiden, The Netherlands). The detection limit was 0.5 fmol 5-HT
per 20 ~1 sample (signal to noise ratio 3).
Data presentation and statistics Four consecutive microdialysis samples with less then 20 % variation were taken as control to and set at 100 %. Data are presented as percentages of control level (mean + S.E.M.) in time. Statistical analysis was performed using Sigmastat for Windows (SPSS, Jandel Corporation). Treatments were compared versus controls using two way analysis of variance (ANOVA) for repeated measurements, followed by Student Newman Keuls test.
Drug effects were evaluated using one way ANOVA for repeated measures on ranks. Level of significance level was set at p<0.05.
Results Co-administration of escitalopram with loxapine on 5-HT levels in ventral hippocampus Administration of loxapine did not induce any significant effects on 5-HT
levels X2~o=10.0, P=0.44). Co-administration of escitalopram (1.5 ~mol/kg s.c.) with 0.1 ~.mollkg s.c. of loxapine induced a significant augmented effect on hippocampal S-HT levels (Treatment F(1,9)= 5.95, P=0.0372, Treatment vs. Time F(1,G4)= 4.18, P=0.0014). Posthoc analysis revealed significance at t= 45 and 60 minutes after injection (see Fig. 1).
Claims (18)
1. The use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
2. The use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
3. The use according to claims 1 or 2 wherein the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, including schizophrenia and schizoaffective disorders and drug abuse.
4. The use according to claim 3 wherein the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of anxiety disorders including general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
5. The use according to claim 3 wherein the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of depression.
6. The use according to claims 1 to 5 wherein the serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
7. The use according to claims 1-6 wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.
8. The use according to claims 1-7 wherein the pharmaceutical composition prepared is adapted for simultaneous administration of the active ingredients.
9. The use according to claim 8 wherein the active ingredients are contained in the same unit dosage form.
10. The use according to claims 1-7 wherein the pharmaceutical composition prepared is adapted for sequential administration of the active ingredients.
11. A pharmaceutical composition comprising Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable Garners or diluents.
12. The pharmaceutical composition according to claims 11 characterised in that the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
13. The pharmaceutical composition according to claims 11 to 12 which is adapted for simultaneous administration of the active ingredients.
14. The pharmaceutical composition according to claim 13 wherein the active ingredients are contained in the same unit dosage form.
15. A kit comprising Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable carriers or diluents.
16. The kit according to claim 15 characterised in that the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
17. The kit according to claim 15 to 16 which is adapted for simultaneous administration of the active ingredients.
18. The kit according to claim 13 which is adapted for sequential administration of the active ingredients.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50080903P | 2003-09-04 | 2003-09-04 | |
| DKPA200301270 | 2003-09-04 | ||
| DKPA200301270 | 2003-09-04 | ||
| PCT/DK2004/000581 WO2005023243A1 (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and loxapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2537747A1 true CA2537747A1 (en) | 2005-03-17 |
Family
ID=34276705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002537747A Abandoned CA2537747A1 (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and loxapine |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1670454A1 (en) |
| JP (1) | JP2007504181A (en) |
| AU (1) | AU2004269858A1 (en) |
| BR (1) | BRPI0413750A (en) |
| CA (1) | CA2537747A1 (en) |
| MX (1) | MXPA06002504A (en) |
| NO (1) | NO20061425L (en) |
| WO (1) | WO2005023243A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500317A (en) | 2004-11-05 | 2006-10-27 | PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM | |
| AR054849A1 (en) | 2005-07-26 | 2007-07-18 | Wyeth Corp | DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM |
| BRPI0709129A2 (en) * | 2006-03-24 | 2011-06-28 | Wyeth Corp | therapeutic combinations for the treatment or prevention of psychotic disorders |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| KR20210047887A (en) * | 2018-09-21 | 2021-04-30 | 에스케이바이오팜 주식회사 | Use of carbamate compounds for the prevention, alleviation or treatment of overlapping seizures |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| PL344331A1 (en) * | 1998-05-22 | 2001-11-05 | Lilly Co Eli | Combination therapy for treatment of refractory depression |
| US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
-
2004
- 2004-09-01 JP JP2006525048A patent/JP2007504181A/en not_active Withdrawn
- 2004-09-01 AU AU2004269858A patent/AU2004269858A1/en not_active Abandoned
- 2004-09-01 MX MXPA06002504A patent/MXPA06002504A/en not_active Application Discontinuation
- 2004-09-01 CA CA002537747A patent/CA2537747A1/en not_active Abandoned
- 2004-09-01 EP EP04762801A patent/EP1670454A1/en not_active Withdrawn
- 2004-09-01 BR BRPI0413750-7A patent/BRPI0413750A/en not_active Application Discontinuation
- 2004-09-01 WO PCT/DK2004/000581 patent/WO2005023243A1/en not_active Application Discontinuation
-
2006
- 2006-03-29 NO NO20061425A patent/NO20061425L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007504181A (en) | 2007-03-01 |
| NO20061425L (en) | 2006-03-29 |
| EP1670454A1 (en) | 2006-06-21 |
| MXPA06002504A (en) | 2006-06-20 |
| WO2005023243A1 (en) | 2005-03-17 |
| BRPI0413750A (en) | 2006-10-24 |
| AU2004269858A1 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100267772A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Agomelatine | |
| US20050234093A1 (en) | Treatment of depression and other affective disorders | |
| EP1545552B1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| CA2537747A1 (en) | The combination of a serotonin reuptake inhibitor and loxapine | |
| US20070042014A1 (en) | Combination of a serotonin reuptake inhibitor and loxapine | |
| US20060223857A1 (en) | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | |
| AU2004296531A1 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| US20070066601A1 (en) | Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| US20080167290A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Amoxapine | |
| CA2537757A1 (en) | The combination of a serotonin reuptake inhibitor and amoxapine | |
| ZA200509588B (en) | The combination of a serotonin reuptake inhibitors and agomelatine | |
| CA2579520A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| MXPA06005127A (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| ZA200409278B (en) | Combination therapy wherein a serotonin reuptake inhibitor is used |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |